BioCentury
ARTICLE | Clinical News

Prurisol: Ph IIb started

November 2, 2016 11:05 PM UTC

Cellceutix began a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate 150 and 200 mg oral Prurisol twice daily for 12 weeks in about 189 patients. The company is developing Prurisol un...

BCIQ Company Profiles

Innovation Pharmaceuticals Inc.